Daniel Ng

934 total citations · 1 hit paper
34 papers, 712 citations indexed

About

Daniel Ng is a scholar working on Urology, Rheumatology and Epidemiology. According to data from OpenAlex, Daniel Ng has authored 34 papers receiving a total of 712 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Urology, 18 papers in Rheumatology and 13 papers in Epidemiology. Recurrent topics in Daniel Ng's work include Urinary Bladder and Prostate Research (20 papers), Pelvic floor disorders treatments (18 papers) and Urinary Tract Infections Management (12 papers). Daniel Ng is often cited by papers focused on Urinary Bladder and Prostate Research (20 papers), Pelvic floor disorders treatments (18 papers) and Urinary Tract Infections Management (12 papers). Daniel Ng collaborates with scholars based in United States, United Kingdom and Canada. Daniel Ng's co-authors include Roy Pardee, Tyler Ross, Jeffrey S. Brown, Mark C. Hornbrook, Gene Hart, John F. Steiner, Noll L. Campbell, Ronald C. Wielage, Sinem Perk and Brandon T. Suehs and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Daniel Ng

33 papers receiving 691 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration

2014 326 citations Daniel Ng et al. profile →

Peers

Countries citing papers authored by Daniel Ng

Since Specialization

Citations

This map shows the geographic impact of Daniel Ng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Ng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Ng more than expected).

Fields of papers citing papers by Daniel Ng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Ng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Ng. The network helps show where Daniel Ng may publish in the future.

Co-authorship network of co-authors of Daniel Ng

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Ng. A scholar is included among the top collaborators of Daniel Ng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Ng. Daniel Ng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment Inertia and Symptom Burden in Anemia of CKD: Insights from the SATISFY Survey in the Middle East, South Africa, and Türkiye 2025 ·International Journal of Nephrology and Renovascular Disease ·Mustafa Arıcı, Saeed Alghamdi, (unknown), (unknown), (unknown), (unknown), Budiwan Sumarsono, Martin Blogg, Daniel Ng, (unknown)	0
2	Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan 2022 ·Frontiers in Medicine ·Hideki Maeda, Daniel Ng	6
3	Quality of recovery assessment of day case and multiday stay patients undergoing elective laparoscopic cholecystectomy 2021 ·Turkish Journal of Surgery ·Matthew D. Campbell, Daniel Ng, (unknown), (unknown), David Bird, Russell Hodgson	1
4	Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System 2020 ·Advances in Therapy ·Greta Lozano‐Ortega, Daniel Ng, Shelagh M. Szabo, Alison Deighton, Bruno Salgado Riveros, (unknown), Katherine Gooch, Cristiano Mendes Gomes	3
5	Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries 2020 ·Journal of the American Medical Directors Association ·(unknown), Aki Shiozawa, Daniel Ng, Rajender R. Aparasu	6
6	Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Case–Control Cohort Analysis 2020 ·Advances in Therapy ·Aki Shiozawa, Sari Hopson, (unknown), Matthias Stoelzel, Daniel Ng, John Hairston	3
7	Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries 2020 ·Advances in Therapy ·Rajender R. Aparasu, (unknown), (unknown), Aki Shiozawa, Daniel Ng, Carol R. Schermer	3
8	A review of published anticholinergic scales and measures and their applicability in database analyses 2019 ·Archives of Gerontology and Geriatrics ·Greta Lozano‐Ortega, Karissa Johnston, Antoinette Cheung, Adrian Wagg, Noll L. Campbell, Roger R. Dmochowski, Daniel Ng	74
9	Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia 2019 ·PharmacoEconomics - Open ·Hélène Parisé, (unknown), Katherine Dea, (unknown), (unknown), Daniel Ng	7
10	The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients with Overactive Bladder 2019 ·Drugs & Aging ·Brandon T. Suehs, (unknown), Jennifer Hayden, Daniel Ng, (unknown)	26
11	An Evaluation of Longitudinal Measures of Anticholinergic Exposure for Application in Retrospective Administrative Data Analyses 2019 ·Advances in Therapy ·Greta Lozano‐Ortega, Shelagh M. Szabo, Antoinette Cheung, Brandon T. Suehs, (unknown), Adrian Wagg, Noll L. Campbell, Roger R. Dmochowski, (unknown), Daniel Ng	7
12	Physician-patient communication about overactive bladder: Results of an observational sociolinguistic study 2017 ·PLoS ONE ·Steven R. Hahn, Pamela Bradt, (unknown), Daniel Ng	8
13	Impact of 2015 Update to the Beers Criteria on Estimates of Prevalence and Costs Associated with Potentially Inappropriate Use of Antimuscarinics for Overactive Bladder 2017 ·Drugs & Aging ·Brandon T. Suehs, (unknown), Daniel Ng, Katherine Gooch	6
14	A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments 2017 ·Neurourology and Urodynamics ·(unknown), Cralen Davis, Rita M. Kristy, Daniel Ng, Carol R. Schermer, (unknown), Brandon T. Suehs	4
15	Impact of coexisting overactive bladder in Medicare patients with osteoporosis 2017 ·Archives of Gerontology and Geriatrics ·(unknown), Ibrahim M. Abbass, Brandon T. Suehs, Daniel Ng, Katherine Gooch, (unknown), (unknown)	5
16	Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder 2016 ·Journal of Managed Care & Specialty Pharmacy ·Sinem Perk, Ronald C. Wielage, Noll L. Campbell, (unknown), Anthony J. Perkins, (unknown), (unknown), Robert W. Klein, Daniel Ng	2
17	Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder 2016 ·Journal of Managed Care & Specialty Pharmacy ·Sinem Perk, Ronald C. Wielage, Noll L. Campbell, (unknown), Anthony J. Perkins, (unknown), (unknown), Robert W. Klein, Daniel Ng	7
18	Retrospective Study Of Utilization Patterns Of Overactive Bladder Therapy In Men In A Commercially Insured Population: The Early Us Mirabegron Experience 2015 ·Value in Health ·Daniel Ng, Joseph W. Shelton, Dan Wei, (unknown), (unknown)	2
19	Current practices in 1st- (1L), 2nd- (2L), and 3rd-line (3L) treatment for metastatic colorectal cancer (mCRC). 2012 ·Journal of Clinical Oncology ·(unknown), Sheikh Usman Iqbal, (unknown), Daniel Ng, Michael Andria, (unknown), (unknown), Lee Stern, (unknown)	1
20	Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin 2009 ·Current Medical Research and Opinion ·James Signorovitch, Mei Sheng Duh, (unknown), Anna Gu, Richard W. Grant, Monika Raut, Samir H. Mody, Jeff Schein, Alan C. Fisher, Daniel Ng	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact